» Articles » PMID: 37992703

Toward a Better Understanding of Cardiovascular Risk in the Transgender and Gender-diverse Community: a Supplement to the Tijuana Declaration

Abstract

On World Heart Day 2022, the Mexican Society of Cardiology, the Inter-American Society of Cardiology, and the World Heart Federation collaborated on a communication regarding the increased risk of adverse cardiovascular health outcomes in transgender and gender-diverse (TGD) individuals. This document, called the Tijuana Declaration, urged the global cardiovascular community to work toward understanding and mitigating this problem. This article aims to unpack the numerous factors that lead to it. An example is the social stigma faced by members of the TGD community, which leads to increased stress and risk for cardiovascular complications. TGD patients are also more likely to have insufficient access to health care, and those that do receive care are often faced with providers that are not adequately educated about the unique needs of their community. Finally, there is some evidence to suggest that gender-affirming hormone therapies have an impact on cardiovascular health, but studies on this subject often have methodological concerns and contradictory findings. Decreasing the incidence of adverse cardiovascular events in this community requires interventions such as educational reform in the medical community, an increase in research studies on this topic, and broader social initiatives intended to reduce the stigma faced by TGD individuals.

References
1.
Streed Jr C, Beach L, Caceres B, Dowshen N, Moreau K, Mukherjee M . Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(6):e136-e148. PMC: 8638087. DOI: 10.1161/CIR.0000000000001003. View

2.
Schutte M, Kleemann R, Nota N, Wiepjes C, Snabel J, TSjoen G . The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS One. 2022; 17(3):e0261312. PMC: 8923509. DOI: 10.1371/journal.pone.0261312. View

3.
Connelly P, Freel E, Perry C, Ewan J, Touyz R, Currie G . Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. Hypertension. 2019; 74(6):1266-1274. PMC: 6887638. DOI: 10.1161/HYPERTENSIONAHA.119.13080. View

4.
Irwig M . Cardiovascular health in transgender people. Rev Endocr Metab Disord. 2018; 19(3):243-251. DOI: 10.1007/s11154-018-9454-3. View

5.
Dunn M, Rosenfeld E, Ananth C, Hutchinson-Colas J, Brandt J . Gender-inclusive research instructions in author submission guidelines: results of a cross-sectional study of obstetrics and gynecology journals. Am J Obstet Gynecol MFM. 2023; 5(6):100911. DOI: 10.1016/j.ajogmf.2023.100911. View